ABSTRACT
Background Treatment of COVID-19 patients with convalescent plasma containing neutralising antibody to SARS-CoV-2 is under investigation as a means of reducing viral loads, ameliorating disease outcomes, and reducing mortality. However, its efficacy might be reduced in those infected with the emerging B.1.1.7 SARS-CoV-2 variant. Here, we report the diverse virological characteristics of UK patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomised controlled trial.
Methods SARS-CoV-2 viral RNA was detected and quantified by real-time PCR in nasopharyngeal swabs obtained from study subjects within 48 hours of admission to intensive care unit. Antibody status was determined by spike-protein ELISA. B.1.1.7 strain was differentiated from other SARS-CoV-2 strains by two novel typing methods detecting the B.1.1.7-associated D1118H mutation with allele-specific probes and by restriction site polymorphism (SfcI).
Findings Of 1260 subjects, 90% were PCR-positive with viral loads in nasopharyngeal swabs ranging from 72 international units [IUs]/ml to 1.7×1011 IU/ml. Median viral loads were 45-fold higher in those who were seronegative for IgG antibodies (n=314; 28%) compared to seropositives (n=804; 72%), reflecting in part the latter group’s possible later disease stage on enrolment. Frequencies of B.1.1.7 infection increased from early November (<1%) to December 2020 (>60%). Anti-SARS-CoV-2 seronegative individuals infected with wild-type SARS-CoV-2 had significantly higher viral loads than seropositives (medians of 1.2×106 and 3.4 ×104 IU/ml respectively; p=2×10−9). However, viral load distributions were elevated in both seropositive and seronegative subjects infected with B.1.1.7 (13.4×106 and 7.6×106 IU/ml; p=0.18).
Interpretation High viral loads in seropositive B.1.1.7-infected subjects are consistent with increased replication capacity and/or less effective clearance by innate or adaptive immune response of B.1.1.7 strain than wild-type. As viral genotype was associated with diverse virological and immunological phenotypes, metrics of viral load, antibody status and infecting strain should be used to define subgroups for analysis of treatment efficacy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by National Institute for Health (UKRIDHSC COVID-19 Rapid Response Rolling Call, The use of convalescent plasma to treat hospitalised and critically ill patients with COVID-19 disease, Grant Reference Number COV19-RECPLAS), the European Commission (SUPPORT-E #101015756), the Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium, the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Rapid European COVID-19 Emergency Research response (RECOVER) consortium by the European Unions Horizon 2020 research and innovation programme (#101003589), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre. ACG is funded by an NIHR Research Professorship (RP-2015-06-18) and MSH by an NIHR Clinician Scientist Fellowship (CS-2016-16-011). DKM is supported by the NIHR throughout the Cambridge NIHR BRC, and the Addenbrookes Charitable Trust.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the principles of the latest version of the Declaration of Helsinki (version Fortaleza 2013), and in accordance with regulatory and legal requirements (EudraCT number: 2015-002340-14). The study was approved by London-Surrey Borders Research Ethics Committee London Centre (18/LO/0660). Written or verbal informed consent, in accordance with regional legislation, is obtained from all patients or their surrogates.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymised virological data presented in this study is available upon requests directed to the corresponding author. Proposals will be reviewed and approved by the sponsor, investigator, and collaborators on the basis of scientific merit. After approval of a proposal, data can be shared through a secure online platform after signing a data access agreement. Study protocol defining the baseline sampling can be accessed via https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/5f5c842bd7bf523730bdda76/1599898680445/REMAP-CAP+COVID-19+Immunoglobulin+Therapy+Domain-Specific+Appendix+V1.01-+01+June+2020.pdf.
